Use of different doses of pulsed short waves in the treatment of patients with osteoarthritis of the knee

A B S T R A C T

Objective
To evaluate the effectiveness of the application of pulsed short waves in the reduction of pain, and functional improvement in patients with osteoarthritis of the knee, and also to investigate changes in treatment between the groups with doses of 17 kilojoules or 33 kilojoules.

Methods
Forty-two female subjects with type II or III osteoarthritis of the knee and over 40 years of age, participated in this study, and were submitted to the application of pulsed short wave doses of 17 or 33 kilojoules. They were evaluated by means of a knee and osteoarthritis score questionnaire, visual analog pain scale and knee flexion goniometry.

Results
The active groups of 17 or 33 kilojoules had less pain and improved function when compared with the control group. There was, however, no significant difference between the active groups.

Vanessa OVANESSIAN¹
Cláudio CAZARINI Júnior¹
Ronaldo Alves da CUNHA¹
Nilza Aparecida de Almeida CARVALHO¹
Thiago Yukio FUKUDA¹

¹Irmandade Santa Casa de Misericórdia de São Paulo, Setor de Fisioterapia, Serviço de Reabilitação. R. Cesário Mota Jr, 112, Santa Cecília, 01277-900, São Paulo, SP, Brazil. Correspondência para/Correspondence to: T.T. FUKUDA. E-mail: tfukuda@scamilo.br.
Conclusion
This study demonstrated that the application of both 17 and 33 kilojoule doses of pulsed short waves is efficient in pain reduction and improved function in the treatment of osteoarthritis of the knee.


RESUMO

Objetivo
Avaliar a eficácia da aplicação de ondas curtas pulsadas na redução da dor e melhora funcional dos pacientes com osteoartrite do joelho. Investigar se há alguma diferença no tratamento entre os grupos com doses de 17 ou 33 kilojoules.

Métodos
Participaram deste estudo 42 mulheres portadoras de osteoartrite no joelho graus II ou III, com idade acima de 40 anos, submetidas à aplicação de ondas curtas pulsadas com doses de 17 ou 33 kilojoules, avaliadas por meio do questionário knee and osteoarthritis score escala visual analógica de dor e goniometria de flexão de joelho.

Resultados
Os grupos ativos de 17 ou 33 kilojoules obtiveram uma melhora do quadro algico e funcional quando comparados com o grupo controle, porém não se encontrou diferença significativa na análise entre os grupos ativos.

Conclusão
Este estudo demonstrou que a aplicação de ondas curtas pulsadas com doses de 17 ou 33 kilojoules é eficaz no tratamento da osteoartrite do joelho.

Termos de indexação: Dor. Modalidade de fisioterapia. Osteoartrite.

INTRODUCTION

Osteoarthritis (OA) is a chronic and multifactorial illness that leads to gradual functional incapacity and affects more than 60% of the world adult population, mainly subjects above 40 years old and female. The knee is one of the joints most affected by this disease, and it causes acute pain, joint stiffness, deformities, hypotrophy of the quadriceps muscles and a gradual reduction in function.

Many interventions are used to relieve pain, improve function, reduce disability and minimize the progression of illness. These interventions include a modified lifestyle, drug therapy, surgery, and specific physical therapy techniques.

Among the techniques used in physical therapy is electromagnetic radiation or short waves that can be applied in continuous or pulsed form.

Pulsed short waves (PSW) are widely used as a therapeutic modality in the treatment of this disease; however, there are few scientific studies that demonstrate the method’s effectiveness and its ideal application dose.

Some authors have used the PSW application with the intention of minimizing the thermal effects generated by conventional continuous application, emphasizing the incremental effects of cellular trophism.

The main effects of PSW application are: increase in local cellular activity, decrease in the inflammatory process, reduction in edema, increase
in the rate of deposit and orientation of fibrin and collagen, increased tissue healing, without interfering with the central nervous system or the hypothalamus\textsuperscript{5,6,9}. Recent studies have shown good therapeutic effects with PSW application, however unsatisfactory results can also be found. These conflicting results seem to be related to the great variation of energy dosages applied. For example, doses of energy between 2.1 and 180 kilojoules (Kj) and length of treatment between 15 and 40 minutes have been found\textsuperscript{1,5,10-12}.

The purpose of this study is to evaluate the effectiveness of PSW application in pain reduction and improved function in patients with knee OA, and to investigate if there is any difference in the treatment between doses of 17Kj and 33Kj.

**METHODS**

The subjects in this study were selected by medical evaluation between March and December 2006 having a diagnosis of knee OA. Forty-two subjects were randomly placed in 3 groups: 14 subjects in the control group (56 years ± 17), 14 subjects in group I (68 years ± 14) and 14 subjects in group II (71 years ± 8). Three subjects in group I and three in group II were unable to attend regularly for PSW therapy.

Female patients above 40 years old were included with a diagnosis of types II or III knee OA, based on the criteria of Gupta et al.\textsuperscript{13}, and who presented more than 3 months of knee joint pain. There was no upper age limit for exclusion.

Exclusion criteria were: surgery or some invasive procedure on the affected knee; physical therapy for knee disorders within the last month; specific drugs utilized such as chondro-protectors, or derivatives of glycosamine, and anti-inflammatory steroids or non-steroids. Paracetamol was the only type of analgesic that was allowed in instances of bouts of pain, except on the day of evaluation. Also excluded were subjects with morbid obesity, or a body mass index above 40, neurological changes, such as limb sensitivity deficits, associated with diseases of the locomotor system, such as meniscal tears, fibromyalgia, traumatic injuries and/or ligaments, presence of metallic implants, cardiac pacemaker or history of tumors.

All the patients were informed of the procedures to be performed and they signed an Informed Consent Form according to the norms of the National Health Council, Resolution 196/69. This study was approved by the ISCMSP’s Ethics Committee on Research, protocol 403/06.

The criteria used for selecting the subjects were determined in advance, and this was carried out by an examiner with no prior knowledge of the treatment to be implemented, and it consisted of the use of a questionnaire, which defined the subjects for the study. The distribution of the subjects into 3 specific groups was randomized and accomplished by drawing lots, with replacement. The same “blind” examiner was responsible for the evaluations before and after treatment (Figure 1).

**Intervention**

The subjects of the active groups (Groups I

![Figure 1. Block-type diagram delineating the proposed study.](image-url)
and II) had been submitted to 3 applications per week of PSW for a total of 9 sessions. The device used was a Diatermed II with a frequency of 27.12 MHz, peak power (Pp) of 250 W and pulse width (Pw) of 400 µs, or 400 x 10^-6 s. The maximum power supplied by the equipment was used with a pulse repetition rate (Prr) of 145 Hz in order to obtain a mean power (Mp) of 14.5 W.

The formula below was used to calculate the Mp:\(^7,14:\)

\[
Mp (W) = Pp (W) \times Pw (s) \times Prr (Hz)
\]

PSW was applied with an electrode on the quadriceps muscle at approximately 5 cm above the top part of the patella and another electrode below the gastrocnemius muscle, with the patient in dorsal decubitus. The knee was kept at approximately 20° in semiflexion.

In group I, the treatment lasted 38 minutes per session with approximately 33 Kj of total energy (E). Group II received 19 minutes of PSW application (t), totaling 17 Kj of energy. The calculation of this amount of energy was obtained via the following equation\(^7,14:\)

\[
E (J) = Mp (W) \times t (s)
\]

The control group was composed of subjects that had not been submitted to treatment. The study sought to compare the results of this group with those obtained in the groups that received energy of 33 Kj or 17 Kj respectively.

**Evaluation**

The subjects were evaluated in two parts: initial evaluation (pre-treatment) and at the end of treatment (post-treatment). The patients that used daily medication such as anti-inflammatories and chondro-protectors were instructed to suspend use 15 days prior to treatment.

The questionnaire used was Knee and Osteoarthritis Outcome Score (KOOS) that consists of 5 subscales: pain, symptoms, sport and recreation function, daily life activities, and quality of life\(^15-18:\). Passive flexion goniometry of the knee joint was also utilized according to the criteria established by Hoppenfeld\(^19:\) and subjective analysis of pain by a visual analog scale (VAS).

**Statistical analysis**

After the data was acquired, the GraphPad Instat statistical program was used to process the obtained values. The data found for the 5 KOOS subscales, goniometry of the knee and VAS between the groups was processed by analysis of variance (ANOVA) - Kruskal-Wallis test. The normalized values were expressed as a mean ± standard error of mean or median (50th percentile). The statistical significance was defined as \(p<0.05\).

An evaluation between groups I and II was also completed by a paired analysis (test-t), with the purpose of observing the relationship between the doses.

Using the KOOS results as the base, knee flexion gain and VAS had the data normalized for an index with the value of the final evaluation minus the initial evaluation and divided by the initial evaluation: (F-I)/I index. The values obtained were compared between active groups I and II in relationship to the control group and between the 3 groups.

**RESULTS**

**KOOS**

The following table shows the specific results of the mean and standard error of mean or median (Table 1). In the analysis of subscale “symptoms”, the values obtained in the control group were 0.0; group I, 0.76 ± 0.38 and group II, 0.53 ± 0.27. There was no significant difference between the groups (\(p>0.05\)).

In the subscale “pain”, the control group presented a value of 0.04 ± 0.09; group I, 0.17 ± 0.71.
and group II, 1.30. Groups I and II presented a significant difference in relation to the control group (p<0.05). In the subscale “activity of daily life”, the subjects in the control group presented a value of 0.1; group I, 0.56 ± 0.15, and group II, 0.85 ± 0.4. There was a statistically significant difference between group I and the control group (p<0.05). In the analysis between the active groups for the subscales “pain” and “activity of daily life”, there was no significant difference (p>0.05).

For “sport and recreation function”, the control group showed a value of -0.05; group I of 1.0 and group II of 1.0. Only group II obtained significant improvement in relation to the control group (p<0.05). In the final data obtained for the scale “quality of life”, the subjects in the control group showed a value of 0.3; group I of 0.85 ± 0.40. There was no significant difference between the groups (p>0.05) (Figure 2).

The subjects of the control group had obtained an index of (F-I)/I of knee flexion during the treatment of 0.05; group I of 0.11 ± 0.05 and group II of 0.0. There were no significant differences when compared to groups I and II and the control group, and when compared to the active groups (p>0.05).

The normalized results of pain relief in the joint were: control group, 0.0; group I, -0.49 ± 0.12 and group II, -0.52 ± 0.05. Groups I and II presented significant improvement when compared to the control group, but the analysis between the active groups did not present a significant difference (p<0.05). All the data presented for KOOS scale, knee flexion and VAS were obtained by the (F-I)/I index.

**DISCUSSION**

The results of this prospective and random study demonstrate an effective means to reduce pain and improve function by utilizing PSW in patients with knee OA, when compared to the control group.

Some divergent aspects were found in the literature for the treatment of patients with OA. The authors did not demonstrate satisfactory therapeutic results in PSW applications with mean power varying between 1.8W and 23W. According to Laufer et al in 2005, an application with mean power of approximately 1.8W is considered non-thermal, while a mean power of 18W would be considered thermal. As for Moffet et al in 1996, they considered a mean power of 23W as sub-thermal. In this study, however, a power of 14.5W was used to minimize the thermal effect, while obtaining satisfactory results with PSW applications when compared with the control group.

<table>
<thead>
<tr>
<th>KOOS</th>
<th>Control n=14</th>
<th>Group I n=11</th>
<th>Group II n=11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>0</td>
<td>0.76 ± 0.38</td>
<td>0.53 ± 0.27</td>
</tr>
<tr>
<td>Pain</td>
<td>0.04 ± 0.09</td>
<td>0.71 ± 0.17</td>
<td>1.3</td>
</tr>
<tr>
<td>ADL</td>
<td>-0.10</td>
<td>0.56 ± 0.15</td>
<td>0.85 ± 0.40</td>
</tr>
<tr>
<td>SRF</td>
<td>-0.05</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>QL</td>
<td>0.30</td>
<td>1</td>
<td>0.8</td>
</tr>
<tr>
<td>VAS</td>
<td>0.00</td>
<td>-0.49 ± 0.12</td>
<td>-0.52 ± 0.05</td>
</tr>
<tr>
<td>Knee Flexion</td>
<td>0.05</td>
<td>0.11 ± 0.05</td>
<td>0</td>
</tr>
</tbody>
</table>

The KOOS subscales (Symptoms, Pain, ADL - Activities of daily life; SRF: Sport and recreational function; QL: Quality of life; VAS: Visual analogic scale, Knee Flexion; n: number of subjects.

**Figure 2.** Comparison between the (F-I)/I index between the 3 groups analyzed for the KOOS subscales.
Notes: KOOS subscales (Symptoms, Pain, ADL: Activities of daily life; SRF: Sport and recreational function; QL: Quality of life); Group I (33 kJ) and Group II (17 kJ).
* p<0.05 (group I x control group); ** p<0.05 (group II x control group).
Beyond these divergences in relation to the specific mean power for production of thermal or non-thermal effects, the ideal dose is the subject of some controversy. For obtaining therapeutic doses, applications have been recommended with total energy above 40 Kj\(^8,12,21\). On the other hand, in the present study, doses of 17 Kj and 33 Kj were utilized for 19 and 38 minutes respectively. Significant results were obtained when compared with the control group. No significant difference was found between these two active groups. It should be stressed that treatment was not administered over a prolonged period of time.

As demonstrated previously, approximate dosages of 40 Kj are the most suitable according to the literature, and for this reason, the group used 33 Kj. The option of using a dosage of 17 Kj was simply an attempt to reach the same therapeutic objective within a shorter time period.

During the second part of this study the “KOOS” questionnaire was utilized for qualitative and quantitative evaluation of the effectiveness of treatment in patients with knee OA. As previously observed, the group that received a dose of 17 Kj presented improvement in “pain” and “sport and recreation function” and the group with a dose of 33 Kj presented improvement in “pain” and “daily life activities” when compared with the control group. Irrespective of the dose used, improvement of function was observed, except for “symptoms” and “quality of life”. Perhaps with a larger sample, a significant difference could be found for these two forms of evaluation.

The active groups with doses of 17 Kj or 33 Kj presented significant differences in the VAS in relation to the control group. However, there was no significant difference between the active groups, bearing in mind the fact that these two doses had provided similar outcomes for pain.

During the analysis of the data of the KOOS subscale “pain”, the groups with 17 Kj and 33 Kj presented statistical differences in relationship to the control group. This information is similar to the data obtained for VAS evaluation, because the two active groups presented significant results.

In the evaluation of knee flexion gain, no significant differences between the groups were found, and this occurred because the initial values of the groups were approximately normal.

A similar study associating exercise and ultrasound was tested by Tuzun et al.\(^2\) in 2003. They applied PSW with a mean power of 8 W and 26 W, and provided doses of 7.2 Kj and 23.76 Kj, finding significant results when compared with the control group.

It was not possible in the present study to compare the active groups with a placebo group because the local ethics committee did not give its approval. In the future, studies including placebo groups and different PSW doses should be performed.

One of the most important contributions of this paper is the fact that a prolonged application is not always necessary. A total time of approximately 20 minutes is enough to reach the therapeutic window suggested in the literature.

**CONCLUSION**

PSW therapy seems to be an effective tool for pain relief and functional improvement in the treatment of patients with knee OA, regardless of the 17 Kj or 33 Kj doses. This conclusion should, however, be restricted to the methodology used.

**REFERENCES**


Received on: 25/1/2008
Final version resubmitted on: 11/7/2008
Approved on: 2/12/2008